MedTrace Logo

Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors

NCT01401933 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2011-11-02

No results posted yet for this study

Summary

This is a phase 1, open-label study designed to determine the interaction of rifampin with linifanib.

Conditions

Interventions

DRUG

Linifanib

QD on Days 1 and 13

DRUG

Rifampin

QD on Days 5-16

Sponsors & Collaborators

Principal Investigators

  • Mark D. McKee, MD · Abbott

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01401933 on ClinicalTrials.gov